This is the primary driver of GLP-1-associated constipation, and it is most pronounced during the first weeks at each new dose level
Nearly 12 percent of Americans have used GLP-1 drugs, with the highest use among women aged 5064, a recent RAND American Life Panel survey found
Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures
Legend may help: Improve joint lubrication and fluid quality Decrease inflammation within the joint Reduce lameness associated with joint irritation Support smoother, more comfortable movement Legend may be administered intravenously (IV) or directly into the joint (IA) depending on the condition being treated
De Wit HM, Vervoort GMM, Jansen HJ, De Grauw WJC, De Galan BE, Tack CJ